Tipranavir Clarithromycin

Drugs that may affect tipranavir include aluminum- and magnesium-based antacids, azole antifungals, clarithromycin, efavirenz, loperamide, NRTIs (ie, didanosine, zidovudine), rifamycins (rifampin), St. John s wort, tenofovir. 

Nevirapine is a moderate inducer of CYP3A metabolism, resulting in decreased levels of amprenavir, indinavir, lopinavir, saquinavir, efavirenz, and methadone (Table 49-4). Drugs that induce the CYP3A system, such as tipranavir, rifampin, rifabutin, and St. John s wort, can decrease levels of nevirapine, whereas those that inhibit CYP3A activity, such as fluconazole, ketoconazole, and clarithromycin, can increase nevirapine levels. 

Clinically important, potentially hazardous interactions with almotriptan, amprenavir, clarithromycin, darunavir, delavirdine, efavirenz, erythromycin, fosamprenavir, indinavir, naratriptan, nelfinavir, nilotinib, ritonavir, rizatriptan, saquinavir, sibutramine, sumatriptan, telithromycin, tipranavir, troleandomycin, zolmitriptan... 

Clinically important, potentially hazardous interactions with atazanavir, azithromycin, bosentan, cholestyramine, clarithromycin, cyclosporine, darunavir, delavirdine, erythromycin, exenatide, fenofibrate, fosamprenavir, gemfibrozil, grapefruit juice, imatinib, itraconazole, red rice yeast, tacrolimus, telithromycin, tipranavir, tolvaptan, verapamil... 

Clinically important, potentially hazardous interactions with amphetamines, aprepitant, astemizole, atazanavir, azithromycin, azole antifungals, clarithromycin, darunavir, dirithromycin, erythromycin, fluoxetine, fosamprenavir, grapefruit juice, imatinib, indinavir, itraconazole, ketoconazole, methylphenidate, nefazodone, nelfinavir, nilotinib, pemoline, phenothiazines, protease inhibitors, quinidine, ritonavir, saquinavir, sertraline, sparfloxacin, sulpiride, telithromycin, thioridazine, tipranavir, tricyclic antidepressants, troleandomycin, voriconazole, zileuton, ziprasidone... 

Drug interactions occur between tipranavir and fluconazole and between tipranavir and clarithromycin, increasing the AUC over a 12 hour period for tipranavir by 56 and 59%, respectively. Care should be taken when administering tipranavir with CYP450 inhibitors and inducers, because clinically significant interactions are possible. Coadministration of tipranavir with antacids decreases the tripranavir AUC by up to 33%. 

Nelfinavir approximately doubles the sierum levels of azithromycin, but the ciinical significance of this is uncertain. Single doses of azithromycin have no effect on the levels of indinavir and nelfinavir. Ritonavir and atazanavir increase clarithromycin leveis. Amprenavir, indinavir and saquinavir do not have a clinically significant effect on clarithromycin pharmacokinetics. Clarithromycin has no important effect on the pharmacokinetics of amprenavir, atazanavir, darunavir, indinavir or ritonavir, but it increases tipranavir levels. Although both clarithromycin and erythromycin markedly raise saquinavir levels, this is not considered clinically important for short courses of these antibacteriais. 

Tipranavir. The manufaeturer notes that tipranavir given with low-dose ritonavir increased the AUC and minimum levels of clarithromycin by 19% and 68%, respectively, and decreased the AUC ofthe 14-hydroxy active metabolite by over 95%. Clarithromycin more than doubled the minimum levels of tipranavir." ... 

---